Navidea Biopharmaceuticals Inc (NAVB)

[sts66]

"There will be people supporting Shrkeli's thesis that they should compare seek to VBD and SC, now that both are approved, especially since VBD and SC were standard of care even before yesterday's announcement. Second, that means that a new trial MAY be wanted by FDA. "

From everything I've read, which is plenty, you cannot do a direct VBD/SC comparison against LS - since both are radioactive tracers, you can't give the same patient both, you'd have no way knowing which tracer you were picking up heat from. And since these women ARE HAVING BREAST CANCER SURGERY, you surely can't propose to do two consecutive surgeries on them to see if LS would find something missed by the other combo.

It's one or the other, period. Attempting to do anything else would be morally and ethically indefensible. Assuming LS is approved (and Pharmalucene sure seems to think it will be), which one would you want to be forced upon you as a patient? One that could potentially kill you with anaphylactic shock or one with no known side effects?